Up­dat­ed: Neu­ron23 launch­es with $113M fi­nanc­ing and eyes dead set on De­nali and Bio­gen

A day af­ter an­nounc­ing two new funds worth $500 mil­lion, West­lake Vil­lage BioPart­ners are an­nounc­ing their lat­est com­pa­ny. And it’s a well-heeled neu­ro start­up, mak­ing a play against some of the field’s biggest tar­gets.

South San Fran­cis­co-based Neu­ron23 an­nounced Wednes­day a $113 mil­lion com­bined Se­ries A and Se­ries B and short-term plans to both take on De­nali and Bio­gen in Parkin­son’s dis­ease and pur­sue the neur­al-side of a tar­get that Bris­tol My­ers Squibb has re­cent­ly pur­sued to great suc­cess else­where in the body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER